 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- CD19/BCMA chimeric antigen receptor T cells / Zhejiang University, CD19/BCMA targeted CAR T-cells / Shanghai Yake Biotech
CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6292;
After lymphodepleting chemotherapy with cyclophosphamide/fludarabine (D-4 to D-2), patients receive a single infusion of 1-2x106 CD19 CAR-T cells and BCMA CAR-T cells per kilogram of body weight at D0...All patients had active severe SLE and had received glucocorticoids, hydroxychloroquine, tacrolimus, total glucosides of paeony, merti-macrolide, leflunomide, azathioprine, methotrexate, cyclophosphamide, immunoglobulin, rituximab, belimumab, and Tetracycline before treatment with CAR-T cells, which were standard treatments that were either ineffective or difficult to withdraw.3 patients received 1x10^6/kg of each of CD19 CAR-T cells and BCMA CAR-T cells, and 9 patients received 2x10^6/kg of each of CD19 CAR-T cells and BCMA CAR-T cells 2x10^6/kg... These data suggest that CD19/BCMA CAR-T cell therapy is well tolerated and can induce rapid and durable remission in severe refractory SLE.
- || New P1 trial: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - May 6, 2023
P1, N=15, Recruiting, Sponsor: Zhejiang University
- ||| CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
New P1 trial, CAR T-Cell Therapy: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis (clinicaltrials.gov) - Mar 2, 2022
P1, N=75, Recruiting, Sponsor: Zhejiang University
- || CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
New P1 trial, CAR T-Cell Therapy: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis (clinicaltrials.gov) - Oct 19, 2021
P1, N=9, Recruiting, Sponsor: Zhejiang University
- || CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
New P1 trial, CAR T-Cell Therapy: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome (clinicaltrials.gov) - Oct 19, 2021
P1, N=9, Recruiting, Sponsor: Zhejiang University
- || CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
New P1 trial, CAR T-Cell Therapy: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma (clinicaltrials.gov) - Oct 19, 2021
P1, N=9, Recruiting, Sponsor: Zhejiang University
- || CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
New P1 trial, CAR T-Cell Therapy: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 31, 2021
P1, N=9, Recruiting, Sponsor: Zhejiang University